Table 4.
Discriminative Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Risk of Hospitalization With Infection Among Persons Without Prevalent Cardiovascular Disease, ARIC Study, 1996–2013
| Exposure Status | C Statistic | Difference From Base Model | 95% Confidence Interval | P Value |
|---|---|---|---|---|
| Overall sample (n = 9,403) | ||||
| Base modela | 0.6414 | 0 | Referent | |
| + prevalent CVD at baseline | 0.6441 | 0.0027 | 0.0011, 0.0042 | <0.001 |
| Participants without prevalent CVD at baseline (n = 8,337) | ||||
| Base modela | 0.6407 | 0 | Referent | |
| + log hs-cTnT only | 0.6448 | 0.0041 | 0.0021, 0.0061 | <0.001 |
| + log NT-proBNP only | 0.6444 | 0.0037 | 0.0015, 0.0058 | 0.001 |
| + log hs-cTnT/ NT-proBNP | 0.6470 | 0.0063 | 0.0036, 0.0090 | <0.001 |
Abbreviations: ARIC, Atherosclerosis Risk in Communities; CVD, cardiovascular disease; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro- B-type natriuretic peptide.
a The base model adjusted for age, sex, race, body mass index, smoking status, alcohol consumption, duration of education (<12 years vs. ≥12 years), frailty, high-sensitivity C-reactive protein, estimated glomerular filtration rate, urinary albumin:creatinine ratio, medication use (aspirin, anticoagulants, and statins), and medical history (hypertension, diabetes, cancer, chronic obstructive pulmonary disease, and abnormal liver function).